There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.

Biologics Quality Control: The Growing Need for Accessible Proteomics

The emergence of mRNA vaccines and cell and gene therapies has pushed innovation in analytical methods.

Emerging Therapies Drive Analytical Advancements

Effective analytics will eliminate failures, deviations, and non-conformances.

 Analyzing Exabytes

Topic

Articles

The company has extended its presence in the US market to support its growing business in the region.

Oxford Genetics Opens First US Office

Merck KGaA completes the divestment of its biosimilars business as part of its strategy to focus on developing a pipeline of innovator drugs.

Merck KGaA Completes $788-Million Divestment of Biosimilars Business

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Technology improvements in analytical testing tools have helped increase understanding of molecules and speed up development processes.

Evolution of Analytical Tools Advances Pharma, But Challenges Remain

Pfizer’s Mylotarg, an anti-body drug conjugate once voluntarily withdrawn, returns to the market under a new dosing regimen for treating leukemia.

FDA Clears Pfizer’s ADC for Leukemia

Changes Everything – LCMS-8060 triple quadrupole mass spectrometer expands UFMS family

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA works with industry on strategies for assuring high-quality regenerative medicines.

Manufacturing Standards Key to Advancing Cellular and Gene Therapies

Joseph F. Pekny is cofounder of Advanced Process Combinatorics, Inc. and professor of Chemical Engineering at Purdue University. 

Spencer Miller is Senior Engineer at Advanced Process Combinatorics, West Lafayette, IN, www.combination.com

Stephen Hunt is director of Process Engineering at KBI BioPharma, shunt@kbibiopharma.com

John Robinson was previously Principal Engineer at KBI Biopharma

Laurence T. Baxter is vice-president of R&D, both at Advanced Process Combinatorics, West Lafayette, IN, www.combination.com

Bob Todd is vice-president of Process Development at KBI BioPharma

Modeling tools help process engineers optimize a biopharmaceutical facility’s capacity.

Using Simulation to Address Capacity Limitations

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Drug repurposing, repositioning, and rescue can be faster, cheaper, and target more diseases than traditional drug discovery approaches.

Expediting the Discovery and Development of Drugs

Natalia Belikova, PhD, is analytical services director at SGS Life Sciences, Lincolnshire, IL.

Hildegard Bruemmer, PhD, is operational laboratory manager at SGS Life Sciences, Germany. 

Forced degradation studies can identify stability problems for drug substance and drug products.

Stepping Up the Pace of Drug Stability Studies

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Analytics

Biologics Quality Control: The Growing Need for Accessible Proteomics

Emerging Therapies Drive Analytical Advancements

Analyzing Exabytes